PT  - JOURNAL ARTICLE
AU  - Zhang, Xiaohan
AU  - Wang, Yajie
AU  - Li, Mansheng
AU  - Li, Haolong
AU  - Zhang, Xiaomei
AU  - Xu, Xingming
AU  - Hu, Di
AU  - Liang, Te
AU  - Zhu, Yunping
AU  - Li, Yongzhe
AU  - Wang, Bingwei
AU  - Yu, Xiaobo
TI  - High-throughput detection of neutralizing antibodies to SARS-CoV-2 variants using flow cytometry
AID  - 10.1101/2023.08.07.23293304
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2023.08.07.23293304
4099  - http://medrxiv.org/content/early/2024/05/10/2023.08.07.23293304.short
4100  - http://medrxiv.org/content/early/2024/05/10/2023.08.07.23293304.full
AB  - Detecting neutralizing antibodies (NAbs) to SARS-CoV-2 variants is crucial for controlling COVID-19 spread. We developed a high-throughput assay for the broad systematic examination of NAbs to eleven SARS-CoV-2 variants, which include D614G, Alpha, Beta, Gamma, Delta, Kappa, and Omicron sub-lineages BA.1-BA.5. The assay is cost-effective, reliable, 35-fold more sensitive than Luminex technology, and can include new variants during SARS-CoV-2 evolution. Importantly, our results highly correlated with a commercial IgG serological assay (R = 0.89), the FDA-approved cPass sVNT assay (R = 0.93), pseudivirus-based neutralizing assay (R = 0.96, R = 0.66, R = 0.65) and live virus based neutralization assay (R = 0.79, R = 0.64) . Using this platform, we constructed a comprehensive overview of the interactions between SARS-CoV-2 variants’ Spike trimer proteins and ACE2 receptors, and identified a polyclonal Ab with broad neutralizing activity. Furthermore, when compared to the D614G variant, we found that the serum NAbs elicited by the third dose vaccine demonstrated decreased inhibition to multiple SARS-CoV-2 variants, including Gamma (0.94×), Alpha (0.91×), Delta (0.91×), Beta (0.81×), Kappa (0.81×), BA.2 (0.44×), BA.1 (0.43×), BA.3 (0.41×), BA.5 (0.35×) and BA.4 (0.33×), in cohort of 56 vaccinated individuals. Altogether, our proteomics platform proves to be an effective tool to detect broad NAbs in the population and aid in the development of future COVID-19 vaccines and vaccination strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Beijing Municipal Natural Science Foundation (M23010 and L234034), National Key R&D Program of China(2022YFE0210400, 2021YFA1301604, 2020YFE0202200), State Key Laboratory of Proteomics (SKLP-O202007), Academic leader of high-level public health technical personnel construction project of Beijing Municipal Health Commission (2022-2-014), Guangdong Province Science and Technology Planning Project (2020B1111100006), Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine. (No: ZYYCXTD-C-202204). We would like to thank the bioinformatics platform of the National Center for Protein Sciences (Beijing) for their support in the data analysis of this project. We also thank Dr. Brianne Petritis for her critical review and editing of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of Beijing Ditan Hospital (No.2021-010-01), and an exemption of informed consent was obtained before sera collection.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors